Save Money with Generic Drugs

Generic drugs can save you up to 80% on the cost of a prescription when compared with the brand name drug. Most often, the savings range from 30% to 50%.

According to the National Association of Chain Drug Stores, the average retail price of a generic prescription drug in 2008 was $35.22. The average retail price of a brand name prescription drug was $137.90. Continue reading

Save With Generics, Understanding Generic Drugs

Nasacort Allergy 24HR(R) Nasal Spray Is Now Available Without a Prescription

Nasacort Allergy 24HR(R) Nasal Spray Is now available without a prescription.  (PRNewsFoto/Sanofi US)Sanofi (EURONEXT: SAN and NYSE: SNY) and its U.S. consumer healthcare division Chattem announced today that Nasacort® Allergy 24HR Nasal Spray is now available over-the-counter (OTC) in the U.S. to relieve the full range of seasonal and year-round nasal allergy symptoms, including nasal congestion, in adults and children 2 years of age and older. Nasacort Allergy 24HR is the first and only medicine in its class to be available at full prescription strength without the need for a prescription.

To view the multimedia assets associated with this release click the following link: http://www.multivu.com/mnr/7098701-nasacort-allergy-24hr-nasal-spray-now-available-without-a-prescription

“Now that Nasacort Allergy 24HR is available over-the-counter, the millions of people who suffer from seasonal and year-round allergies have easier access to the gold standard treatment for nasal allergy symptoms,” said Zan Guerry, Chief Executive Officer, Chattem.

More than 60 million Americans suffer from seasonal and year-round hay fever and other upper respiratory allergies. Symptoms of nasal allergies, which include sneezing, itchy nose, runny nose and nasal congestion, can lead to a major disruption in the quality of life for both adults and children. Nasal allergies can interfere with sleep, outdoor activities, and for children, their performance in school.

Nasacort is part of the most effective class of medicine for the treatment of hay fever and other upper respiratory allergies, and the only medicine in this class available OTC. It works differently than other over-the-counter treatments to relieve the full range of nasal allergy symptoms, including nasal congestion, by stopping more of the chemical responses that cause those symptoms.

“The launch of Nasacort Allergy 24HR represents our long-standing commitment to helping individuals living with allergies,” said Anne Whitaker, President North America Pharmaceuticals, Sanofi US. “This milestone builds on our heritage in the allergy category and our expertise in prescription to over-the-counter switches as we continue to expand our global consumer healthcare organization.”

Nasacort received approval from the US Food and Drug Administration (FDA) to switch from prescription to OTC on October 11, 2013, and is now available on retail shelves nationwide. For more information, visit www.nasacort.com.

Save With Generics ,

Mylan Launches Generic Prandin® Tablets

Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg. This product is the generic version of Novo Nordisk’s Prandin®, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.(1) The company received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.

Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg, had U.S. sales of approximately $212.95 million for the 12 months ending Sept. 30, 2013, according to IMS Health.

Currently, Mylan has 187 ANDAs pending FDA approval representing $93.7 billion in annual sales, according to IMS Health. Forty-one of these pending ANDAs are potential first-to-file opportunities, representing $24.1 billion in annual brand sales, for the 12 months ending June 30, 2013, according to IMS Health. When including ANDAs associated with Mylan’s recent acquisition of Agila, the company now has a total of 287 ANDAs pending FDA approval.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don’t take our word for it. See for yourself. See inside. mylan.com

Save With Generics ,

Perrigo Receives FDA Final Approval For Generic Equivalent To Prandin®

PERRIGO COMPANY LOGO / Perrigo Company. (PRNewsFoto/Perrigo Company)Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has received final approval from the U.S. Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin® Tablets (repaglinide tablets) and has commenced shipment of product. Perrigo previously launched the 0.5 mg strength in 2013.

Prandin® tablets (repaglinide tablets), are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus and have annual sales of approximately $250 million, as measured by Symphony Health Solutions.

Perrigo’s Chairman, President and CEO Joseph C. Papa stated, “This approval shows the talent and expertise of our R&D and regulatory affairs departments. This is another example of Perrigo’s commitment to bring new products to market and deliver on our mission to provide quality, affordable healthcare to consumers.”

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri®. The Company is the world’s largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo’s mission is to offer uncompromised “Quality Affordable Healthcare Products™,” and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America. Visit Perrigo on the Internet (http://www.perrigo.com).

 

Save With Generics ,